Oncorus, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2019 | $54 M | No. 2 | $50 to $250 million | equity, options | SEC | |
| Mar 2016 | $61 M | No. 1 | $50 to $250 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Oncorus, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2019).
SEC Form D · Dec 2019
The industry group it chose in its notices: Other.
SEC Form D · Dec 2019
That is all the official record says: Oncorus, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
22 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Deerfield Healthcare Innovations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Deerfield Mgmt HIF, L.P | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Deerfield Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| MPM Asset Management Investors BV2014 LLC | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Asset Management Investors SunStates Fund LLC | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Asset Management LLC | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Bioimpact LLC | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2014 (B), L.P. | Venture capital | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2014 GP LLC | Venture capital | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2014 LLC | Venture capital | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2014, L.P. | Venture capital | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Oncology Impact Management GP LLC | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM SunStates Fund GP LLC | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM SunStates Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM SunStates GP Managing Member LLC | Other | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Oncology Impact Fund (Cayman) Management L.P. | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Spencer Nam | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2020) | SEC Form 3 |
| UBS Oncology Impact Fund L.P. | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 30 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christophe Queva | Executive officer | Dec 2019 |
| John McCabe | Executive officer | Dec 2019 |
| Theodore Ashburn | Executive officer | Dec 2019 |
| Mitchell Finer | Executive officer | Sep 2018 |
| Cyrus Mozayeni | Executive officer | Nov 2016 |
| Marc Recht | Executive officer | Nov 2016 |
| Thomas Chalberg | Executive officer | Nov 2016 |
| Briggs Morrison | Director | Dec 2019 |
| Cameron Wheeler | Director | Dec 2019 |
| Luke Evnin | Director | Dec 2019 |
| Mary Kay Fenton | Director | Dec 2019 |
| Mitchell Finer | Director | Dec 2019 |
| Robert Kirkman | Director | Dec 2019 |
| Spencer Nam | Director | Dec 2019 |
| Theodore Ashburn | Director | Dec 2019 |
| Alon Lazarus | Director | Sep 2018 |